Teva Pharmaceutical Industries Ltd's Executive Vice President of European Commercial, Richard Daniell, filed a Form 144 notice of proposed sale of 25,000 ordinary shares on November 9, 2026, with the sale to be executed through Citigroup Global Markets Inc. on NYSE.

Key Highlights

  • Proposed seller: Richard Daniell, Executive VP European Commercial at Teva Pharmaceutical Industries Ltd
  • Shares proposed for sale: 25,000 ordinary shares with an aggregate market value of $1,072,789.40
  • Indicative price basis: The filing states an indicative market price of $42.911576 per share was used to calculate the aggregate market value
  • Nature of acquisition: Securities were acquired through a stock option exercise and sale, with compensation cited as the nature of payment
  • Acquisition and sale date: Both the acquisition date and approximate date of sale are listed as November 9, 2026
  • Shares outstanding: 1,166,826,784 ordinary shares reported as outstanding
  • Prior three-month sales: The filing reports nothing to report for securities sold during the past three months

Richard Daniell's Proposed Share Sale via Stock Option Exercise at Teva Pharmaceutical

According to the Form 144 filing submitted to the U.S. Securities and Exchange Commission, Richard Daniell, who holds the title of Executive VP European Commercial at Teva Pharmaceutical Industries Ltd (NYSE:TEVA), has provided notice of a proposed sale of 25,000 ordinary shares. The broker named to execute the transaction is Citigroup Global Markets Inc., located at 390 Greenwich Street, New York, NY 10013, and the sale is designated for the New York Stock Exchange.

The filing discloses that the 25,000 ordinary shares were acquired on November 9, 2026, through a stock option exercise and sale, with Teva Pharmaceutical Industries Limited named as the person from whom the securities were acquired. The nature of payment is listed as compensation. The aggregate market value of the shares proposed for sale is reported as $1,072,789.40, based on an indicative market price of $42.911576 per share, as stated in the filing's remarks section. No gift designation was indicated for this transaction.

The filing notes that there are no securities of the issuer sold during the past three months by the person for whose account the proposed sale is being made. Total ordinary shares outstanding are reported as 1,166,826,784. By submitting this notice, the filing represents that Daniell "does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed," as stated in the form's attestation language.

What Was Disclosed

Teva Pharmaceutical Industries Ltd officer Richard Daniell filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 25,000 ordinary shares acquired via stock option exercise, with an aggregate market value of $1,072,789.40, to be sold through Citigroup Global Markets Inc. on the NYSE.